Nastech, Schwarz Pharma Inc. deal

NSTK reacquired U.S. marketing rights to its intranasal scopolamine for motion sickness, which it had licensed to Schwarz in 1997. NSTK will pay a buyback fee of $250,000 and share product revenues with Schwarz until it has paid back Schwarz's investment of $3.5 million plus interest. NSTK said it will seek a new partner for the product, which is under FDA review. ...